Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivitis sicca. Although DED represents a large prevalent pool in the G7 markets, the condition is underdiagnosed and few drugs are approved to treat it. As such, commercial opportunity abounds in this space. Indeed, despite the challenges in drug development for DED, the pipeline is robust, with a number of drugs in active late-phase development. With the expected launch of five new drugs for DED and the generic entry of AbbVie’s blockbuster Restasis in the United States, the DED therapy market is set to be dynamic and competitive over the next decade.

QUESTIONS ANSWERED

  • How large is the prescription drug-treatable DED population in the G7 countries? How will drug-treatment rates change over the 2019-2029 forecast period?
  • What is the current size of the DED market for key prescription therapies in the G7 countries? How will key events, including the generic availability of Restasis in the United States, influence the market over the next decade?
  • What is the current state of DED treatment? Which are the most important drug classes / drugs and why? What are interviewed experts’ insights on current treatment options?
  • What are the biggest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs? What therapies of note are progressing in earlier phases?

CONTENT HIGHLIGHTS

Geographies: United States, EU5, Japan.

Primary research: 20 country-specific interviews with thought-leading ophthalmologists and optometrists. Supported by survey data collected for this and other DRG research.

Epidemiology: Total prevalence of DED by country, including diagnosed prevalence and prescription drug-treatment rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key therapies for DED through 2029, segmented by brands / generics.

Emerging therapies: Phase III / PR: 9 drugs; coverage of select Phase II drugs.

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Dry Eye - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Himanshu Jain, M.S. Pharm ; Emma McFadden, PhD; Fjoralba Kristo, MD, MPH ; Shefali Gulati, MBA Pharm

Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.

Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.

Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy. 

Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.

 

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods.

Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.

Shefali Gulati, Associate analyst, is part of the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group.

She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She comes with one year of experience working on multiple client projects revolving around opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds a MBA degree in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research (NIPER) in India and Bachelor’s in Pharmacy from DIPSAR.


Related Reports

Dry Eye - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

In dry eye disease (DED), the normal functioning of the tear film is disrupted, resulting in troublesome ocular symptoms such as eye burning, and presentin...

View Details

Dry Eye - Access & Reimbursement - Detailed, Expanded Analysis (US)

The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of S...

View Details